FDA approved sealant Neomend offers Progel Pleural Air Leak Sealant, the only FDA approved pleural air leak sealant on the U.S. market, indicating a defensible product with regulatory clearance and high relevance to thoracic surgery centers seeking proven intraoperative leak reduction and shorter hospital stays.

Clinical efficacy signal A multi-center U.S. study shows Progel PALS reduces intraoperative air leaks and cuts hospital stay by nearly two days, providing a compelling value proposition for hospitals focused on patient outcomes, length-of-stay costs, and payer metrics.

Wound care platform Neomend’s Proprietary Hydrogel Technology Platform enables expansion into wound sealing, post-surgical adhesion prevention, and site-specific drug delivery, creating cross-sell opportunities with surgical suites and wound care programs.

Growing revenue potential With a revenue range of one to ten million dollars and a recent funding level of twenty million, Neomend demonstrates growth potential and capacity for scaled manufacturing and clinical adoption, signaling readiness for expanded distribution agreements.

Targeted market fit Operating in medical equipment manufacturing with a focused product for thoracic surgery, Neomend presents opportunities to partner with hospitals, distributors, and contract sales organizations in the U.S. and to leverage existing surgical outcomes metrics to drive adoption.